• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

一体化二硫键桥接能够生成具有模块化载药功能的抗体偶联物。

All-in-one disulfide bridging enables the generation of antibody conjugates with modular cargo loading.

作者信息

Dannheim Friederike M, Walsh Stephen J, Orozco Carolina T, Hansen Anders Højgaard, Bargh Jonathan D, Jackson Sophie E, Bond Nicholas J, Parker Jeremy S, Carroll Jason S, Spring David R

机构信息

Yusuf Hamied Department of Chemistry, University of Cambridge Cambridge CB2 1EW UK

Cancer Research UK Cambridge Institute, University of Cambridge Cambridge CB2 0RE UK

出版信息

Chem Sci. 2022 Jul 20;13(30):8781-8790. doi: 10.1039/d2sc02198f. eCollection 2022 Aug 4.

DOI:10.1039/d2sc02198f
PMID:35975158
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9350601/
Abstract

Antibody-drug conjugates (ADCs) are valuable therapeutic entities which leverage the specificity of antibodies to selectively deliver cytotoxins to antigen-expressing targets such as cancer cells. However, current methods for their construction still suffer from a number of shortcomings. For instance, using a single modification technology to modulate the drug-to-antibody ratio (DAR) in integer increments while maintaining homogeneity and stability remains exceptionally challenging. Herein, we report a novel method for the generation of antibody conjugates with modular cargo loading from native antibodies. Our approach relies on a new class of disulfide rebridging linkers, which can react with eight cysteine residues, thereby effecting all-in-one bridging of all four interchain disulfides in an IgG1 antibody with a single linker molecule. Modification of the antibody with the linker in a 1 : 1 ratio enabled the modulation of cargo loading in a quick and selective manner through derivatization of the linker with varying numbers of payload attachment handles to allow for attachment of either 1, 2, 3 or 4 payloads (fluorescent dyes or cytotoxins). Assessment of the biological activity of these conjugates demonstrated their exceptional stability in human plasma and utility for cell-selective cytotoxin delivery or imaging/diagnostic applications.

摘要

抗体药物偶联物(ADCs)是有价值的治疗实体,它利用抗体的特异性将细胞毒素选择性地递送至表达抗原的靶标,如癌细胞。然而,目前其构建方法仍存在许多缺点。例如,使用单一修饰技术以整数增量调节药物与抗体比率(DAR),同时保持均一性和稳定性仍然极具挑战性。在此,我们报告了一种从天然抗体生成具有模块化载药量的抗体偶联物的新方法。我们的方法依赖于一类新型的二硫键重桥连接头,其可与八个半胱氨酸残基反应,从而用单个接头分子实现IgG1抗体中所有四个链间二硫键的一体化桥连。以1:1的比例用接头修饰抗体,通过用不同数量的有效载荷连接柄对接头进行衍生化,从而能够快速且选择性地调节载药量,以允许连接1、2、3或4个有效载荷(荧光染料或细胞毒素)。对这些偶联物的生物学活性评估表明,它们在人血浆中具有出色的稳定性,可用于细胞选择性细胞毒素递送或成像/诊断应用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/543c/9350601/3e91f9f9c5e2/d2sc02198f-f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/543c/9350601/47631a2893d8/d2sc02198f-f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/543c/9350601/0138871435f7/d2sc02198f-f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/543c/9350601/556d44e18db0/d2sc02198f-f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/543c/9350601/68fa80035b42/d2sc02198f-f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/543c/9350601/3e91f9f9c5e2/d2sc02198f-f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/543c/9350601/47631a2893d8/d2sc02198f-f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/543c/9350601/0138871435f7/d2sc02198f-f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/543c/9350601/556d44e18db0/d2sc02198f-f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/543c/9350601/68fa80035b42/d2sc02198f-f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/543c/9350601/3e91f9f9c5e2/d2sc02198f-f5.jpg

相似文献

1
All-in-one disulfide bridging enables the generation of antibody conjugates with modular cargo loading.一体化二硫键桥接能够生成具有模块化载药功能的抗体偶联物。
Chem Sci. 2022 Jul 20;13(30):8781-8790. doi: 10.1039/d2sc02198f. eCollection 2022 Aug 4.
2
A general approach for the site-selective modification of native proteins, enabling the generation of stable and functional antibody-drug conjugates.一种用于天然蛋白质位点选择性修饰的通用方法,可实现稳定且具有功能的抗体-药物偶联物的生成。
Chem Sci. 2018 Nov 9;10(3):694-700. doi: 10.1039/c8sc04645j. eCollection 2019 Jan 21.
3
Bridged Cysteine Conjugations.桥接半胱氨酸共轭。
Methods Mol Biol. 2020;2078:113-129. doi: 10.1007/978-1-4939-9929-3_8.
4
Enabling the formation of native mAb, Fab' and Fc-conjugates using a bis-disulfide bridging reagent to achieve tunable payload-to-antibody ratios (PARs).使用双二硫键桥接试剂实现天然单克隆抗体、Fab'片段和Fc缀合物的形成,以实现可调节的载药量与抗体比率(PARs)。
Chem Sci. 2023 Mar 9;14(14):3752-3762. doi: 10.1039/d2sc06318b. eCollection 2023 Apr 5.
5
Antibody-Drug Conjugates (ADCs) Derived from Interchain Cysteine Cross-Linking Demonstrate Improved Homogeneity and Other Pharmacological Properties over Conventional Heterogeneous ADCs.源于链间半胱氨酸交联的抗体-药物偶联物(ADC)相较于传统的异质性ADC,展现出更高的均一性和其他药理特性。
Mol Pharm. 2015 Nov 2;12(11):3986-98. doi: 10.1021/acs.molpharmaceut.5b00432. Epub 2015 Oct 2.
6
Disulfide re-bridging reagents for single-payload antibody-drug conjugates.用于单载物抗体药物偶联物的二硫键重桥连试剂。
Chem Commun (Camb). 2023 Aug 10;59(65):9868-9871. doi: 10.1039/d3cc02980h.
7
Bridging disulfides for stable and defined antibody drug conjugates.用于稳定且明确的抗体药物偶联物的桥连二硫键
Bioconjug Chem. 2014 Jun 18;25(6):1124-36. doi: 10.1021/bc500148x. Epub 2014 May 23.
8
Influence of disulfide bond isoforms on drug conjugation sites in cysteine-linked IgG2 antibody-drug conjugates.二硫键异构体对半胱氨酸连接的 IgG2 抗体药物偶联物中药物结合点的影响。
MAbs. 2018 May/Jun;10(4):583-595. doi: 10.1080/19420862.2018.1440165. Epub 2018 Mar 6.
9
Enzymatic conjugation using branched linkers for constructing homogeneous antibody-drug conjugates with high potency.使用分支连接子进行酶促偶联以构建高效能的均一抗体-药物偶联物。
Org Biomol Chem. 2017 Jul 5;15(26):5635-5642. doi: 10.1039/c7ob01027c.
10
In vitro and in vivo evaluation of cysteine and site specific conjugated herceptin antibody-drug conjugates.半胱氨酸及其定点偶联曲妥珠单抗抗体药物偶联物的体内外评价。
PLoS One. 2014 Jan 14;9(1):e83865. doi: 10.1371/journal.pone.0083865. eCollection 2014.

引用本文的文献

1
A platform for SpyCatcher conjugation to native antibodies.一个用于将SpyCatcher与天然抗体偶联的平台。
Chem Sci. 2025 May 6. doi: 10.1039/d5sc02286j.
2
Homogeneous antibody-drug conjugates with dual payloads: potential, methods and considerations.具有双负载的均相抗体药物偶联物:潜力、方法与考量
MAbs. 2025 Dec;17(1):2498162. doi: 10.1080/19420862.2025.2498162. Epub 2025 May 5.
3
Methods for the Generation of Single-Payload Antibody-Drug Conjugates.单有效载荷抗体-药物偶联物的生成方法。

本文引用的文献

1
Divinylpyrimidine reagents generate antibody-drug conjugates with excellent efficacy and tolerability.二乙烯基嘧啶试剂可生成具有优异疗效和耐受性的抗体药物偶联物。
Chem Commun (Camb). 2022 Feb 8;58(12):1962-1965. doi: 10.1039/d1cc06766d.
2
Antibodies to watch in 2022.2022 年值得关注的抗体药物
MAbs. 2022 Jan-Dec;14(1):2014296. doi: 10.1080/19420862.2021.2014296.
3
Interconversion of Unexpected Thiol States Affects the Stability, Structure, and Dynamics of Antibody Engineered for Site-Specific Conjugation.意想不到的巯基状态的转换会影响为定点偶联而工程化的抗体的稳定性、结构和动态。
ChemMedChem. 2025 May 19;20(10):e202500132. doi: 10.1002/cmdc.202500132. Epub 2025 Mar 19.
4
Therapeutic potential of antibody-drug conjugates possessing bifunctional anti-inflammatory action in the pathogenies of rheumatoid arthritis.具有双功能抗炎作用的抗体-药物偶联物在类风湿关节炎发病机制中的治疗潜力
Arthritis Res Ther. 2024 Dec 19;26(1):216. doi: 10.1186/s13075-024-03452-0.
5
NSPs: chromogenic linkers for fast, selective, and irreversible cysteine modification.NSPs:用于快速、选择性和不可逆半胱氨酸修饰的显色连接剂。
Chem Sci. 2024 Jun 14;15(28):10997-11004. doi: 10.1039/d4sc01710b. eCollection 2024 Jul 17.
6
Homogeneous multi-payload antibody-drug conjugates.均一化多载物抗体药物偶联物。
Nat Chem. 2024 Jun;16(6):854-870. doi: 10.1038/s41557-024-01507-y. Epub 2024 May 17.
7
Antibody-drug conjugates in cancer therapy: innovations, challenges, and future directions.抗体药物偶联物在癌症治疗中的应用:创新、挑战与未来方向。
Arch Pharm Res. 2024 Jan;47(1):40-65. doi: 10.1007/s12272-023-01479-6. Epub 2023 Dec 28.
8
The Nitrile Bis-Thiol Bioconjugation Reaction.双硫醇化反应。
J Am Chem Soc. 2024 Jan 10;146(1):274-280. doi: 10.1021/jacs.3c08762. Epub 2023 Dec 20.
9
Disulfide re-bridging reagents for single-payload antibody-drug conjugates.用于单载物抗体药物偶联物的二硫键重桥连试剂。
Chem Commun (Camb). 2023 Aug 10;59(65):9868-9871. doi: 10.1039/d3cc02980h.
10
Enabling the formation of native mAb, Fab' and Fc-conjugates using a bis-disulfide bridging reagent to achieve tunable payload-to-antibody ratios (PARs).使用双二硫键桥接试剂实现天然单克隆抗体、Fab'片段和Fc缀合物的形成,以实现可调节的载药量与抗体比率(PARs)。
Chem Sci. 2023 Mar 9;14(14):3752-3762. doi: 10.1039/d2sc06318b. eCollection 2023 Apr 5.
Bioconjug Chem. 2021 Aug 18;32(8):1834-1844. doi: 10.1021/acs.bioconjchem.1c00286. Epub 2021 Aug 9.
4
Sulfatase-cleavable linkers for antibody-drug conjugates.用于抗体药物偶联物的硫酸酯酶可裂解连接子。
Chem Sci. 2020 Jan 27;11(9):2375-2380. doi: 10.1039/c9sc06410a.
5
Diethynyl Phosphinates for Cysteine-Selective Protein Labeling and Disulfide Rebridging.二硫代磷酸酯用于半胱氨酸选择性蛋白质标记和二硫键重连。
Angew Chem Int Ed Engl. 2021 Jul 5;60(28):15359-15364. doi: 10.1002/anie.202100683. Epub 2021 Jun 3.
6
Innovative Bioconjugation Technology for Antibody-Drug Conjugates: Proof of Concept in a CD30-Positive Lymphoma Mouse Model.抗体药物偶联物的创新生物偶联技术:在 CD30 阳性淋巴瘤小鼠模型中的概念验证。
Bioconjug Chem. 2021 Mar 17;32(3):595-606. doi: 10.1021/acs.bioconjchem.1c00058. Epub 2021 Feb 25.
7
Site-selective modification strategies in antibody-drug conjugates.抗体药物偶联物中的位点选择性修饰策略。
Chem Soc Rev. 2021 Jan 21;50(2):1305-1353. doi: 10.1039/d0cs00310g. Epub 2020 Dec 8.
8
Contemporary Approaches for Site-Selective Dual Functionalization of Proteins.当代蛋白质位点选择性双官能化方法。
Angew Chem Int Ed Engl. 2021 Jun 14;60(25):13757-13777. doi: 10.1002/anie.202012034. Epub 2021 Feb 26.
9
DiPODS: A Reagent for Site-Specific Bioconjugation via the Irreversible Rebridging of Disulfide Linkages.DiPODS:通过二硫键的不可逆重桥连实现定点生物偶联的试剂。
Bioconjug Chem. 2020 Dec 16;31(12):2789-2806. doi: 10.1021/acs.bioconjchem.0c00590. Epub 2020 Nov 19.
10
Expeditious Total Synthesis of Hemiasterlin through a Convergent Multicomponent Strategy and Its Use in Targeted Cancer Therapeutics.通过聚合多组分策略快速全合成海兔毒素及其在靶向癌症治疗中的应用。
Angew Chem Int Ed Engl. 2020 Dec 14;59(51):23045-23050. doi: 10.1002/anie.202010090. Epub 2020 Oct 12.